Molecular medicines for cancer : (Record no. 72278)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06243cam a2200745Ki 4500 |
| 001 - CONTROL NUMBER | |
| control field | 9781315269214 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220711212834.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 180921s2018 flu ob 001 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9781315269214 |
| -- | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 131526921X |
| -- | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9781351978378 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 1351978373 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9781351978354 |
| -- | (electronic bk. : Mobipocket) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 1351978357 |
| -- | (electronic bk. : Mobipocket) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9781351978361 |
| -- | (electronic bk. : EPUB) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 1351978365 |
| -- | (electronic bk. : EPUB) |
| 082 04 - CLASSIFICATION NUMBER | |
| Call Number | 616.99/4061 |
| 245 00 - TITLE STATEMENT | |
| Title | Molecular medicines for cancer : |
| Sub Title | concepts and applications of nanotechnology / |
| 300 ## - PHYSICAL DESCRIPTION | |
| Number of Pages | 1 online resource (pages) |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Remark 2 | Cover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Foreword; Preface; Acknowledgments; Editors; Contributors; Section I : Nanotechnology-Based Approaches to Target Cancer; Chapter 1: Nanomedicines for Cancer; 1.1 Introduction; 1.2 Nanomedicines in Clinical Use and Under Clinical Trials; 1.2.1 Liposome-Based Nanomedicines; 1.2.2 Polymer-Based Nanomedicines; 1.2.3 Protein-Based Nanomedicines; 1.2.4 Micelles-Based Nanomedicines; 1.2.5 Nanotechnology-Based Miscellaneous Nanomedicines; 1.3 Targeting Mechanism of Nanomedicines; 1.3.1 Passive Targeting |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Remark 2 | 1.3.2 Active Targeting1.3.3 Stimuli-Responsive Nanomedicine; 1.4 Design Aspect of Nanomedicines; 1.4.1 Vascular Transport; 1.4.2 Transvascular Transport; 1.4.3 Interstitial Transport; 1.4.4 Intracellular Transport; 1.5 Enhancing Nanomedicine Translation through Clinically Relevant Models; 1.5.1 Standard Xenograft Models with Human Stroma Components; 1.5.2 Patient-Derived Tumor Xenograft (PDX) Model; 1.5.3 Humanized PDX Model; 1.5.4 Human Metastatic Site Model; 1.6 Challenges and Current Limitations; 1.7 Advantages and Disadvantages of Nanotechnology; 1.8 Conclusion; References |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Remark 2 | Chapter 2: Effect of Nanocarrier Size/Surface on Molecular Targeting in Cancer2.1 Introduction; 2.2 Particle Size in Tumor Targeting; 2.2.1 Tumor Type and Pore Cutoff Size; 2.2.2 Circulation in Bloodstream; 2.2.3 Nanoparticle Trafficking and Tumor Internalization; 2.2.4 Cellular Uptake and Cell-Particle Interactions; 2.3 Particle Shape on Tumor Targeting; 2.3.1 Circulation in Bloodstream; 2.3.2 Nanoparticle Transportation and Tumor Internalization; 2.3.3 Cellular Uptake and Cell-Particle Interactions; 2.4 Influence of Nanocarrier Surface Properties on Tumor Targeting |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Remark 2 | 2.4.1 Circulation in Bloodstream2.4.2 Nanoparticle Transportation and Tumor Internalization; 2.4.3 Surface Functionalization with Targeting Tumors; 2.5 Conclusion; References; Chapter 3: Nanocarrier Systems for Anticancer Drug Delivery at the Subcellular Level; 3.1 Introduction; 3.2 Mitochondrial Targeted Drug Delivery; 3.2.1 Mitochondria and Cancer Therapy; 3.2.2 Mitochondrial Drug Delivery; 3.2.2.1 Mitochondriotropic Conjugated Nanocarriers; 3.2.2.2 Mitochondrial-Penetrating Peptide (MPP) Conjugated Nanocarriers; 3.2.2.3 Mitochondrial Targeting Signal (MTS) Conjugated Nanocarriers |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Remark 2 | 3.3 Nuclear Targeted Drug Delivery3.3.1 The Nucleus: Role in Cancer Treatment; 3.3.2 Nuclear Drug Delivery; 3.3.2.1 Nuclear Localization Signal (NLS) Conjugated Nanocarriers; 3.3.2.2 Other Approaches; 3.4 Lysosomal Targeted Drug Delivery; 3.4.1 Lysosomes; 3.4.2 Lysosomal Cell Death; 3.4.3 Lysosomal Drug Delivery; 3.4.3.1 Nanocarriers Containing Lysosomotropic Agents; 3.4.3.2 Nanocarriers Modified with Cathepsin-Specific Substrates; 3.4.3.3 Ceramide Containing Nanocarriers; 3.4.3.4 Metal Nanoparticles; 3.4.3.5 pH-Responsive Nanocarriers; 3.5 Endoplasmic Reticulum (ER) Targeted Drug Delivery |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | The field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology. |
| 700 1# - AUTHOR 2 | |
| Author 2 | Chitkara, Deepak, |
| 700 1# - AUTHOR 2 | |
| Author 2 | Mittal, Anupama, |
| 700 1# - AUTHOR 2 | |
| Author 2 | Mahato, Ram I., |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | https://www.taylorfrancis.com/books/9781315269214 |
| 856 42 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | eBooks |
| 264 #1 - | |
| -- | Boca Raton : |
| -- | CRC Press, |
| -- | [2018] |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 588 ## - | |
| -- | OCLC-licensed vendor bibliographic record. |
| 650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | Tumors. |
| 650 #0 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | Chemotherapy. |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | HEALTH & FITNESS / Diseases / General |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Clinical Medicine |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Diseases |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Evidence-Based Medicine |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Internal Medicine |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Pharmacology |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | MEDICAL / Pharmacy |
| 650 #7 - SUBJECT ADDED ENTRY--SUBJECT 1 | |
| -- | TECHNOLOGY / Nanotechnology |
No items available.